Why in News?

The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorization to Qdenga, making it India's first approved dengue vaccine. Developed by the Japanese pharmaceutical company Takeda, Qdenga is a live-attenuated tetravalent vaccine designed to protect against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). While the approval marks a significant breakthrough in India's fight against dengue, clinical trial data indicate important concerns regarding its effectiveness against certain virus serotypes, especially in individuals who have never been infected with dengue before.

Background

• Dengue is one of India's most serious vector-borne diseases. India contributes nearly one-third of the global dengue burden, with seasonal outbreaks causing thousands of hospitalizations every year. The disease is transmitted by the Aedes aegypti mosquito and is caused by four genetically distinct serotypes of the dengue virus.
• Since infection with one serotype provides lifelong immunity only against that specific serotype, subsequent infections by different serotypes may become more severe due to a phenomenon known as Antibody-Dependent Enhancement (ADE). Therefore, developing a safe and effective dengue vaccine has remained one of the biggest challenges in tropical medicine.

What is Qdenga?

Qdenga (TAK-003) is:

• A live-attenuated tetravalent dengue vaccine.
• Developed by Takeda Pharmaceuticals (Japan).
• Approved in more than 40 countries.
• Recommended for individuals aged 4–60 years.
• Can be administered irrespective of previous dengue infection.
• Its objective is to provide balanced immunity against all four dengue virus serotypes simultaneously.

Understanding Dengue Serotypes

The dengue virus exists in four serotypes:

• DENV-1
• DENV-2
• DENV-3
• DENV-4

Each serotype behaves differently.

An individual infected with one serotype becomes immune only to that serotype but remains vulnerable to the remaining three.

Antibody-Dependent Enhancement (ADE): The Biggest Challenge

• One of the most dangerous characteristics of dengue infection is Antibody-Dependent Enhancement (ADE).

How ADE Works

• A person contracts DENV-1.
• The body develops antibodies against DENV-1.
• Later the person gets infected with DENV-3.
• Instead of protecting the individual, antibodies against DENV-1 may help DENV-3 enter immune cells more efficiently.
• This significantly increases the risk of Severe Dengue, Dengue Hemorrhagic Fever (DHF), or Dengue Shock Syndrome (DSS).

Hence,

• The ideal dengue vaccine must provide equal protection against all four serotypes.
• Failure against even one serotype can increase future disease severity.

Major Concern: Protection Against DENV-3

When researchers analyzed protection against individual serotypes:

Good Protection

✔ DENV-1

✔ DENV-2

Limited Protection

❌ DENV-3

Among seronegative children, vaccinated individuals showed:

• 25% higher risk of DENV-3 infection compared to unvaccinated children.

This observation raises concern that the vaccine may unintentionally create conditions favorable for Antibody-Dependent Enhancement (ADE).

Why Screening Before Vaccination Matters

• Researchers from Imperial College London recently modeled the public-health impact of Qdenga.
• Their conclusion:
• Individuals—particularly children—who have never been infected with dengue should ideally undergo screening for previous dengue exposure before vaccination.

This approach could substantially reduce ADE-related risks.

Way Forward

India should:

• Continue post-marketing surveillance of Qdenga.
• Establish nationwide vaccine safety monitoring.
• Develop affordable dengue antibody screening tests.
• Strengthen vector control.
• Accelerate indigenous dengue vaccine research.
• Increase public awareness regarding mosquito prevention.

Conclusion

The approval of Qdenga represents a landmark achievement in India's public health system and offers hope against one of the country's most widespread mosquito-borne diseases. Nevertheless, the available scientific evidence indicates that protection is not uniform across all dengue virus serotypes. The observed safety signal against DENV-3 in seronegative individuals highlights the importance of cautious implementation, continued surveillance, and evidence-based vaccination strategies. A balanced approach combining vaccination, screening, mosquito control, and public awareness will be essential for effectively reducing India's dengue burden.

Dengue